← Leaderboards
Xiao Zhen Zhou
Beth Israel Deaconess Medical Center
$3,160,397
Attributed
$5,853,692
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2006–19$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$5,853,692 · 4
By mechanism
R01$5,513,692 · 3
R21$340,000 · 1
Top collaborators
- Kun Ping Lu6 shared
- Nathanael Schiander Gray3 shared
- Eng H. Lo3 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Kun Ping Lu$22,478,971
- Ming Hui Chen$4,823,776
- David J Friedman$7,089,711
- Christos S Mantzoros$9,054,294
- Francesca N Delling$5,534,111
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadMouse ModelCellsTumor Suppressor ProteinsIn VivoTumorTelomeraseNeoplastic CellMolecularCell LineProteinsSeriesMalignant NeoplasmsTumorigenicityKnock-OutCancer CellCancer TherapyIn Vivo ModelIn VitroLoss Of HeterozygosityMediatingMutantAnticancer TreatmentGenes
Grant awards (13)
Role of Tau Conformations in Vascular Contribution to Cognitive Impairment and Dementia$686,160
R01 · FY2019 · AG
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$635,224
R01 · FY2019 · CA
Role of Tau Conformations in Vascular Contribution to Cognitive Impairment and Dementia$686,160
R01 · FY2018 · AG
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$654,869
R01 · FY2018 · CA
Role of Tau Conformations in Vascular Contribution to Cognitive Impairment and Dementia$704,410
R01 · FY2017 · AG
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$673,119
R01 · FY2017 · CA
Role of the Putative Tumor Suppressor PinX1 in the Etiology of Liver Cancer$293,000
R01 · FY2010 · CA · contact PI
Role of the Putative Tumor Suppressor PinX1 in the Etiology of Liver Cancer$293,000
R01 · FY2009 · CA · contact PI
Role of the Putative Tumor Suppressor PinX1 in the Etiology of Liver Cancer$293,000
R01 · FY2008 · CA · contact PI
Role of the Putative Tumor Suppressor PinX1 in the Etiology of Liver Cancer$293,000
R01 · FY2007 · CA · contact PI
Role of the Putative Tumor Suppressor PinX1 in the Etiology of Liver Cancer$301,750
R01 · FY2006 · CA · contact PI
PinX1, a Putative Tumor Suppressor for Prostate Cancer$170,000
R21 · FY2004 · CA
PinX1, a Putative Tumor Suppressor for Prostate Cancer$170,000
R21 · FY2003 · CA